yl-13027
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 19, 2019 (NCT03869632)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- TGF-beta receptor type-1INHIBITOR
TGFBR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06662669 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2024 | Shanghai YingLi Pharmaceutical Co. Ltd. |
| NCT06199466 | Phase 1 | Jan 22, 2024 | University of Texas at Houston |
| NCT05457517 | Phase 1/Phase 2 (Phase 2) | Sep 24, 2022 | Shanghai YingLi Pharmaceutical Co. Ltd. |
| NCT05228600 | Phase 1 | May 17, 2022 | Shanghai YingLi Pharmaceutical Co. Ltd., University of Cincinnati, University of Texas at Houston |
| NCT03869632 | Phase 1 | Mar 19, 2019 | Shanghai YingLi Pharmaceutical Co. Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai YingLi Pharmaceutical Co. Ltd. | For profit | 4 | 4 | 2 | 2019 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 1 | 2022 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1